Table 3:

Review of recent clinical outcomes of 3D image-guided brachytherapy for uterine cervical cancer

Author (reference)	Year	Number of patients	Imaging for 3D planning	Median follow-up (months)	LC rate	Late toxicity Grade 3 or higher
Tan et al. [11]	2009	28	CT	23	96%	11%
Kang et al. [12]	2010	97	CT	41	97% (3-year)	4%
Pötter et al. [13]	2011	156	MRI	42	95% (3-year)	4% (rectum), 2% (bladder)
Charra-Brunaud et al. [14]	2012	117	CT (82%), MRI (18%)	24	79% (2-year)	3%
Tharavichitkul et al. [15]	2013	47	CT (68%), MRI (32%)	26	98%	2%
Lindegaard et al. [16]	2013	140	MRI	36	91% (3-year)	3% (GI tract), 1% (urinary tract)
Dyk et al. [17]	2014	134	MRI	29	82%	NR
Murakami et al. [18]	2014	51	CT	39	92% (3-year)	2% (GI tract), 0% (bladder)
Rijkmans et al. [19]	2014	83	CT (52%), MRI (48%)	42	NR	8%
Gill et al. [20]	2015	128	MRI	24	92% (2-year)	1%
Simpson et al. [21]	2015	76	CT fused with MRI	17	95%	2%
Mazeron et al. [22]	2015	225	CT (10%), MRI (90%)	39	87%	NR
Zolciak-Siwinska et al. [23]	2016	216	CT	52	90% (5-year)	4% (rectum), 3% (bladder)
Ribeiro et al. [24]	2016	170	CT (4%), MRI (96%)	37	96% (5-year)	7% (rectosigmoid), 6% (urinary tract)
Sturdza et al. [25]	2016	731	CT (19%), MRI (81%)	43	89% (5-year)	7% (GI tract), 5% (bladder)
Present study	2016	80	CT	60	94% (5-year)	0% (rectosigmoid), 1% (bladder)

CT = computed tomography, GI = gastrointestinal, LC = local control, MRI = magnetic resonance imaging, NR = not reported.